Wednesday, July 29, 2020 11:35:35 PM
It's on the wall >>>>>>>>
CONCLUSIONS
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)
https://www.nejm.org/doi/full/10.1056/NEJMoa2024671
CONCLUSIONS
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)
https://www.nejm.org/doi/full/10.1056/NEJMoa2024671
Recent MRNA News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:03 PM
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 • ACCESS Newswire • 04/15/2026 11:00:00 AM
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:32:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:21:25 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Moderna Resolves Global Patent Litigation with Arbutus/Genevant • ACCESS Newswire • 03/03/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 02:56:47 PM
- European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 02/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:49:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 03:26:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:03:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2026 09:02:04 PM
